A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
Axsome Therapeutics (AXSM) is back in focus after the FDA granted Priority Review to its AXS-05 program for Alzheimer's disease agitation, alongside reported 66% full-year 2025 net product revenue growth that is drawing fresh investor attention. See our latest analysis for Axsome Therapeutics. At a share price of $164.49, Axsome's recent 13.27% 90 day share price return and 38.48% 1 year total shareholder return suggest momentum has picked up again after a softer year to date performance, with Priority Review for AXS-05 and new Phase 3 activity in solriamfetol adding fresh catalysts alongside a busy conference schedule. If this kind of clinical and regulatory newsflow has your attention, it may be a suitable moment to scan other healthcare names through our 32 healthcare AI stocks as potential additions to your watchlist. Axsome now trades at $164.49 with very strong multi year returns behind it, a reported 66% net product revenue uptick in 2025, and key AXS-05 news on the ho
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics Highlights Auvelity's $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference [Yahoo! Finance]Yahoo! Finance
- Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)GlobeNewswire
- Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- 2 Under-the-Radar Stocks to Buy and Hold [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 2/23/26 - Beat
AXSM
Sec Filings
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- AXSM's page on the SEC website